Danaher Corporation $DHR Shares Sold by Credit Agricole S A

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Credit Agricole S A trimmed its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 41.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 639,818 shares of the conglomerate's stock after selling 452,265 shares during the quarter. Credit Agricole S A owned approximately 0.09% of Danaher worth $131,163,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Fayez Sarofim & Co lifted its position in shares of Danaher by 0.6% in the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after acquiring an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC raised its stake in Danaher by 4.8% in the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after purchasing an additional 50 shares during the last quarter. MGO One Seven LLC lifted its holdings in Danaher by 1.3% in the 4th quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate's stock valued at $984,000 after purchasing an additional 53 shares in the last quarter. Hills Bank & Trust Co boosted its stake in Danaher by 0.3% during the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock worth $3,693,000 after purchasing an additional 53 shares during the last quarter. Finally, Sageworth Trust Co boosted its stake in Danaher by 2.3% during the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock worth $493,000 after purchasing an additional 54 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analysts Set New Price Targets

DHR has been the subject of a number of recent research reports. Barclays reiterated an "overweight" rating and issued a $225.00 target price (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Guggenheim reiterated a "buy" rating and issued a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. Royal Bank Of Canada reissued an "outperform" rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Leerink Partners upped their price target on Danaher from $225.00 to $230.00 and gave the company an "outperform" rating in a research report on Wednesday, April 23rd. Finally, Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $247.61.

Danaher Trading Down 3.4%

DHR traded down $7.2480 during trading hours on Thursday, reaching $204.1520. The company's stock had a trading volume of 3,172,582 shares, compared to its average volume of 4,191,163. The stock has a market cap of $146.18 billion, a PE ratio of 43.44, a P/E/G ratio of 2.95 and a beta of 0.73. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The business's 50-day moving average is $200.45 and its 200-day moving average is $199.55.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter last year, the firm earned $1.72 earnings per share. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.